AN2 Therapeutics Ownership | Who Owns AN2 Therapeutics?


OverviewForecastFinancialsChart

AN2 Therapeutics Ownership Summary


AN2 Therapeutics is owned by 27.46% institutional investors, 25.39% insiders, and 47.16% retail investors. Citadel advisors is the largest institutional shareholder, holding 5.22% of ANTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.68% of its assets in AN2 Therapeutics shares.

ANTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAN2 Therapeutics27.46%25.39%47.16%
SectorHealthcare Stocks 487.91%11.08%-398.99%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Citadel advisors1.55M5.22%$3.34M
Almitas capital1.43M4.73%$1.51M
Vanguard group1.04M3.47%$1.43M
Pfizer715.29K2.37%$758.21K
Renaissance579.77K1.94%$800.09K
Stonepine capital management544.49K1.80%$577.16K
Two sigma advisers, lp528.30K1.77%$729.05K
Bank of nova scotia459.19K1.52%$486.75K
Bank of montreal /can/422.08K1.41%$582.47K
Two sigma investments, lp400.33K1.34%$552.46K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Stonepine capital management544.49K0.57%$577.16K
Almitas capital1.43M0.38%$1.51M
Pfizer715.29K0.13%$758.21K
Act advisors, llc.13.20K0.01%$16.76K
Bridgeway capital management162.20K0.01%$223.84K
Two sigma advisers, lp528.30K0.00%$729.05K
Highline wealth partners5.00K0.00%$6.35K
Renaissance579.77K0.00%$800.09K
Two sigma investments, lp400.33K0.00%$552.46K
Xtx topco26.04K0.00%$27.61K

Top Buyers

HolderShares% AssetsChange
Stonepine capital management544.49K0.57%544.49K
Bank of montreal /can/422.08K0.00%422.08K
Two sigma advisers, lp528.30K0.00%407.40K
Two sigma investments, lp400.33K0.00%222.49K
Goldman sachs group224.19K0.00%195.81K

Top Sellers

HolderShares% AssetsChange
Bml capital management---5.75M
Octagon capital advisors lp---3.22M
Frazier life sciences management---2.09M
Ra capital management---2.00M
Tcg crossover management---1.56M

New Positions

HolderShares% AssetsChangeValue
Bank of montreal /can/422.08K0.00%422.08K$582.47K
Act advisors, llc.13.20K0.01%13.20K$16.76K
Hrt financial lp12.68K0.00%12.68K$13.00K
Royal bank of canada2.81K-2.81K$6.00K
Bnp paribas arbitrage, snc312.00-312.00$431.00

Sold Out

HolderChange
Jpmorgan chase-49.00
Wells fargo & company/mn-128.00
Fmr-300.00
Coldstream capital management-783.00
California state teachers retirement system-9.25K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202536-8,284,557-36.41%271.46%1730.77%5-54.55%
Mar 31, 202537-14,340,830-1.29%472.01%13-45.83%1157.14%
Dec 31, 20243719.35%14,528,9307.52%482.37%2450.00%7-
Sep 30, 202431-31.11%13,513,224-30.40%451.06%16-20.00%7-46.15%
Jun 30, 202445-16.67%19,415,9093.64%651.04%20-35.48%13-18.75%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv733.39K2.68%-16.03K
Vanguard Institutional Extnd Mkt Idx Tr179.94K0.66%-81.99K
Fidelity Extended Market Index117.68K0.43%-968.00
Bridgeway Ultra-Small Company Market59.00K0.22%-
iShares Micro-Cap ETF51.33K0.19%-
Fidelity Total Market Index48.79K0.18%-104.00
BlackRock Extended Equity Market K33.77K0.11%-14.00
Bridgeway Ultra-Small Company33.20K0.11%33.20K
Fidelity Series Total Market Index30.27K0.11%-
Extended Equity Market Fund K32.76K0.11%-654.00

Recent Insider Transactions


DateNameRoleActivityValue
May 28, 2025Leonard Braden Michael-Sell$218.00K
Jun 02, 2025Easom Eric Chief Executive OfficerBuy$10.66K
May 28, 2025Leonard Braden Michael-Sell$2.32M
May 30, 2025Leonard Braden Michael-Sell$429.25K
May 28, 2025Leonard Braden Michael-Sell$116.00K

Insider Transactions Trends


DateBuySell
2025 Q3--
2025 Q225
2025 Q1-4
2024 Q418-
2024 Q312

ANTX Ownership FAQ


Who Owns AN2 Therapeutics?

AN2 Therapeutics shareholders are primarily institutional investors at 27.46%, followed by 25.39% insiders and 47.15% retail investors. The average institutional ownership in AN2 Therapeutics's industry, Biotech Stocks , is 307.10%, which AN2 Therapeutics falls below.

Who owns the most shares of AN2 Therapeutics?

AN2 Therapeutics’s largest shareholders are Citadel advisors (1.55M shares, 5.22%), Almitas capital (1.43M shares, 4.73%), and Vanguard group (1.04M shares, 3.47%). Together, they hold 13.43% of AN2 Therapeutics’s total shares outstanding.

Does Blackrock own AN2 Therapeutics?

BlackRock is not among the top 10 institutional shareholders of AN2 Therapeutics.

Who is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested?

Stonepine capital management is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.57% of its assets in 544.49K AN2 Therapeutics shares, valued at 577.16K$.

Who is the top mutual fund holder of AN2 Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of AN2 Therapeutics shares, with 2.68% of its total shares outstanding invested in 733.39K AN2 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools